Taysha: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 05, 2024

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company focused on advancing adeno-associated virus -based gene therapies for severe monogenic diseases of the central nervous system, announced that, on July 3, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 484,000 shares of the Company's common stock in connection with their employment.